Afatinib Appears To Be Better First-Line Option For EGFR-mutated Lung Cancer
Lung Cancer, News
According to clinical results recently presented at the ESMO Asia 2015 Congress in Singapore, patients with EGFR-activating mutations in advanced lung cancer have more clinical benefits from being treated with ... Read more